 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | rebonuputemcel (IDCT) / DiscGenics
Phase classification: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration (clinicaltrials.gov) - Jan 25, 2023
P1, N=60, Completed, Sponsor: DiscGenics, Inc.
Phase classification: P1/2 --> P1
- ||| rebonuputemcel (IDCT) / DiscGenics
Trial completion, Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration (clinicaltrials.gov) - Dec 1, 2022
P1/2, N=60, Completed, Sponsor: DiscGenics, Inc.
Phase classification: P1/2 --> P1 Unknown status --> Completed | Trial completion date: Apr 2021 --> Nov 2022 | Trial primary completion date: Apr 2020 --> Feb 2022
- || rebonuputemcel (IDCT) / DiscGenics
Trial completion, Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration (clinicaltrials.gov) - Nov 30, 2022
P1/2, N=38, Completed, Sponsor: DiscGenics, Inc.
Unknown status --> Completed | Trial completion date: Apr 2021 --> Nov 2022 | Trial primary completion date: Apr 2020 --> Feb 2022 Unknown status --> Completed | Trial completion date: Aug 2021 --> Nov 2022 | Trial primary completion date: Feb 2021 --> Feb 2022
- || rebonuputemcel (IDCT) / DiscGenics
Enrollment closed: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration (clinicaltrials.gov) - Mar 4, 2020
P1/2, N=60, Active, not recruiting, Sponsor: DiscGenics, Inc.
Unknown status --> Completed | Trial completion date: Aug 2021 --> Nov 2022 | Trial primary completion date: Feb 2021 --> Feb 2022 Recruiting --> Active, not recruiting
- | rebonuputemcel (IDCT) / DiscGenics
Enrollment open: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration (clinicaltrials.gov) - Aug 7, 2019
P1/2, N=38, Recruiting, Sponsor: DiscGenics, Inc.
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || rebonuputemcel (IDCT) / DiscGenics
New P1/2 trial: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Disc Degeneration (clinicaltrials.gov) - May 19, 2019
P1/2, N=38, Not yet recruiting, Sponsor: DiscGenics, Inc.
- | rebonuputemcel (IDCT) / DiscGenics
Enrollment open, Trial completion date, Trial primary completion date: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration (clinicaltrials.gov) - Mar 19, 2018
P1/2, N=60, Recruiting, Sponsor: DiscGenics, Inc.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Nov 2019 --> Apr 2020
- | rebonuputemcel (IDCT) / DiscGenics
Trial initiation date: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration (clinicaltrials.gov) - Feb 5, 2018
P1/2, N=60, Not yet recruiting, Sponsor: DiscGenics, Inc.
Not yet recruiting --> Recruiting | Trial completion date: Nov 2020 --> Apr 2021 | Trial primary completion date: Nov 2019 --> Apr 2020 Initiation date: Nov 2017 --> Feb 2018
- | rebonuputemcel (IDCT) / DiscGenics
New P1/2 trial: Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration (clinicaltrials.gov) - Nov 20, 2017
P1/2, N=60, Not yet recruiting, Sponsor: DiscGenics, Inc.